News Aflibercept for Macular Degeneration Maintains Improvement by Medscape • 2012/11/21 • 0 Comments VIEW 1 and VIEW 2 follow-up at 96 weeks showed maintenance of visual acuity, but less frequent dosing is possible with aflibercept vs ranibizumab. Medscape Medical News Full Story →